Comparative Pharmacology
Head-to-head clinical analysis: HALDOL SOLUTAB versus LOXITANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALDOL SOLUTAB versus LOXITANE.
HALDOL SOLUTAB vs LOXITANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Haloperidol is a typical antipsychotic that primarily antagonizes dopamine D2 receptors in the mesolimbic pathway, also blocking alpha-adrenergic, histamine H1, and muscarinic receptors.
Loxapine is a typical antipsychotic that exerts its effects primarily by blocking dopamine D2 receptors in the mesolimbic pathway. It also has affinity for serotonin 5-HT2A, histamine H1, alpha1-adrenergic, and muscarinic receptors.
1 to 15 mg orally once daily (tablet or orally disintegrating tablet). For acute agitation, 2.5 to 10 mg intramuscularly every 1 to 8 hours. Maximum oral dose: 100 mg/day; maximum IM dose: 20 mg/day.
Oral: Initial 10 mg twice daily; may increase up to 250 mg/day in divided doses. IM: 12.5-50 mg every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life averages 21 hours (range 12-38 hours) in healthy adults; clinically significant for once-daily dosing.
12-18 hours (terminal). Steady state achieved within 3-5 days; dosing adjustments for renal/hepatic impairment.
Renal (approximately 30-40% as metabolites, <1% unchanged); biliary/fecal (approximately 15-20%); significant enterohepatic recirculation.
Renal excretion accounts for 50-60% (primarily as metabolites, <1% unchanged). Fecal/biliary elimination accounts for 25-35% (via bile).
Category C
Category C
Antipsychotic
Antipsychotic